Spyre Therapeutics Inc. stocks have been trading up by 25.46 percent after pivotal clinical trial progress strengthened investor optimism.
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Should Watch
- Stifel raised its price target on Spyre Therapeutics from $70 to $92 and reiterated a Buy rating, leaning on upcoming readouts and the broad potential of TL1A therapies.
- Enrollment for the rheumatoid arthritis arm of the SKYWAY trial finished early, pulling week‑12 topline data forward to Q3 2026 and tightening Spyre’s catalyst timeline.
- The SKYLINE ulcerative colitis trial is enrolling ahead of plan, with Part A induction data for SPY001 expected in Q2 2026 and a scheduled 2026/04/13 topline release and conference call.
- Psoriatic arthritis and axial spondyloarthritis SKYWAY sub‑studies remain on track for Q4 2026 readouts, and SYRE shares jumped more than 6% on the latest clinical update.
- New employee stock options at a $48.90 strike and recent, opaque Form 4 filings show ongoing insider and staff exposure to SYRE, though without clear directional signals.
Live Update At 12:34:04 EDT: On Monday, April 13, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 25.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
SYRE has been trading like a classic biotech momentum story. In late March, Spyre Therapeutics was sitting around the low‑$40s. By early April, the stock pressed into the high‑$40s and low‑$50s, and on 2026/04/13 it spiked as high as $75 before closing near $64.35. For short‑term traders, that is a huge expansion in range and volatility.
The intraday tape on 2026/04/13 shows a wild open near $67 with a fast push to $75, followed by heavy profit‑taking and choppy recovery around $64–$66. SYRE offered multiple $1–$2 swings within minutes, ideal for disciplined day trading but dangerous for anyone chasing.
More Breaking News
- Gerdau Stock Climbs Amid Price Target Boosts by Major Banks
- RIG Stock Slips As Clarksons Cuts Rating, Price Target
- Bloom Energy Stock Surges As Oracle AI Power Deal Fuels Rally
- Robinhood (HOOD) Draws Bullish Targets Despite Price Cuts
Under the hood, Spyre Therapeutics remains a classic clinical‑stage biotech: no material revenue, steep losses, but a strong cash position. SYRE reported about $857.2M in cash and a current ratio of 13.3, with zero long‑term debt. Return metrics are deeply negative, reflecting heavy research and development spending rather than operating strength. For traders, that means the SYRE chart and news flow — not traditional earnings — will continue to drive the next big move.
Why Traders Are Watching SYRE Right Now
SYRE is on every catalyst trader’s radar because the story lines up: strong trend, rising targets, and a packed news calendar. Stifel’s move to raise its price target on Spyre Therapeutics from $70 to $92, while reiterating a Buy rating, is not just a number change. It is a clear signal from the Street that the firm sees more upside as the TL1A program matures.
The core of the SYRE setup is execution. Spyre Therapeutics finished enrollment early for the rheumatoid arthritis sub‑study in its SKYWAY phase 2 basket trial. That pulled week‑12 topline data into Q3 2026 instead of later in the year. Faster enrollment usually means strong site interest and smooth trial logistics — things traders love to see ahead of data.
At the same time, the SKYLINE ulcerative colitis platform trial is enrolling ahead of plan. Initial Part A data for SPY001 is expected in Q2 2026, and SYRE has already circled 2026/04/13 for the Part A induction topline release plus a conference call. That kind of precise date is a magnet for event‑driven trading.
Layer on top the psoriatic arthritis and axial spondyloarthritis SKYWAY sub‑studies, which are pacing toward Q4 2026 readouts, and you get a dense series of shots on goal. The market already reacted: SYRE shares jumped over 6% on the latest clinical update. For now, every good execution headline has been rewarded.
Conclusion
For active traders, SYRE is a textbook news‑driven biotech. Spyre Therapeutics has cash, no debt, and a pipeline whose value will swing sharply on each new trial readout. The big call from Stifel — lifting the price target to $92 and sticking with a Buy rating — adds external conviction right as SYRE approaches the SKYLINE Part A data drop and a string of SKYWAY readouts.
The option grants to new non‑executive employees, set at a $48.90 strike and vesting over four years, suggest Spyre Therapeutics is still building out its team, aligning staff with long‑term share performance. Recent Form 4 filings show insider ownership shifting, but the summaries give no detail on whether those trades were buys, sells, or awards. With that limited color, serious traders will focus far more on the trial calendar and the tape than on vague filings.
SYRE will not trade like a slow, steady blue chip. It will gap, spike, and flush around each clinical headline. As Tim Sykes likes to remind his community, “Volatility is opportunity only if you respect the risk and cut losses quickly.” That mindset lines up with the broader rule echoed across many trading communities: risk management must come before the hunt for big wins. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”. Spyre Therapeutics fits that description perfectly — a high‑potential, high‑risk biotech where preparation, not hope, decides who wins.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.